Why Spark's stock price is down 30 percent

Despite posting its first-ever profitable quarter, shares of Spark Therapeutics were trading down 30 percent Tuesday morning after the Philadelphia gene therapy company reported two patients had an adverse immune response to its experimental hemophilia A therapy. Spark said the immune response problem was addressed and it is moving forward with late-stage testing of the treatment, known as SPK-8011 that will begin by the end of the year. Hemophilia A is a genetic bleeding disorder caused by missing…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news